A Phase 2 interventional study of Tafasitamab and Lenalidomide in Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Sun Yat-sen University. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse — 9 open to participants now, 9 under way, 2 of them phase 3. orelabrutinib · Lymphoma, Large B-Cell, Diffuse.
Among the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 10th largest by planned enrollment, is one of 2 that started in 2026, is one of 8 in phase 2, and was the 11th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →9 of the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18–70
Sun Yat-sen University · Sites in China
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 60+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 70+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 29 is below the median of 45 across 1,499 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 39 across the 11 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 7 most frequent:
Sun Yat-sen University is the lead sponsor of 1,692 studies on the registry; 620 are open to participants now.
17 studies in Lymphoma, Large B-Cell, Diffuse by Sun Yat-sen University: 10 open now, 10 under way, 1 of them phase 3. Of 2 finished, 0 (0%) have results posted.
Among the 17 studies in Lymphoma, Large B-Cell, Diffuse by Sun Yat-sen University, this one is the 13th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2026, is one of 9 in phase 2, and was the 17th registered.
Sun Yat-sen University’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among Sun Yat-sen University’s 17 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
This is a Phase II, Single-Arm, Open-Label, Prospective, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (TAFA) combined with Lenalidomide, Rituximab, and Orelabrutinib in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tafasitamab in combination with lenalidomide, rituximab and orelabrutinib for 4 cycles, and then receive tafasitamab and lenalidomide for additional 8 cycles. Each treatment cycle is 28 days.
Drug: Tafasitamab · Drug: Lenalidomide · Drug: Rituximab · Drug: Orelabrutinib
12mg/kg, IV, C1-3: D1, 8, 15, 22 (with an additional loading dose on C1D4), C4-12: D1, 15.
25mg, PO, day 1-21 of cycle 1-12
375mg/m2, IV, day 1 of cycle 1-4
150mg or 100mg, PO, day 1-28 of cycle 1-4
Complete response rate (CRR)
CRR was defined as the proportion of patients who achieve complete response (CR)
Time frame: Up to 12 cycles ( each cycle is 28 days)
Objective response rate (ORR)
ORR was defined as the proportion of patients who achieve complete response (CR) or partial response (PR)
Time frame: Up to 12 cycles (each cycle is 28 days)
Disease control rate (DCR)
DCR was defined as the proportion of patients who achieve complete response (CR), partial response (PR) and stable disease (SD)
Time frame: Up to 12 cycles (each cycle is 28 days)
Duration of Response (DoR)
DoR was defined as the time from the patients's first efficacy assessment achieving CR or PR until disease progression
Time frame: up to 3 years
Duration of Complete Response (DoCR)
DoCR was defined as the time from the patients's first efficacy assessment achieving CR until disease progression
Time frame: up to 3 years
Progression-free survival (PFS)
PFS was defined as the time from the date of the first administration of any study drug to the date of tumor progression or death from any cause
Time frame: up to 3 years
Overall survival (OS)
OS was defined as the time from the date of the first administration of any study drug until death from any cause
Time frame: up to 3 years
Time to Response (TTR)
TTR was defined as the time from the initiation of treatment to the patients's first efficacy assessment achieving CR or PR
Time frame: Up to 12 cycles (each cycle is 28 days)
Adverse events
The incidence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs)
Time frame: Up to 28 days after the last dose of study drug
Change in Quality of Life
Quality of life will be assessed using the EORTC QLQ-C30 questionnaire
Time frame: Up to 3 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
Of 210 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 24 months is below that.
Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orelabrutinib
Lymphoma, Large B-Cell, Diffuse →